An Assortment of Journal Abstracts to Enhance Oncology Care : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
Tucidinostat plus R-CHOP improved efficacy and was safe in previously untreated DLBCL expressing MYC and BCL2.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Abemaciclib plus fulvestrant improved PFS vs fulvestrant alone in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.
Northwestern Memorial Foundation raises funds to support the relentless pursuit of better medicine.
A new type of liquid biopsy test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research…
CHICAGO, June 1, 2024 – The American Cancer Society (ACS) and the American Society of Clinical Oncology (ASCO) today announced an expanded…
An abstract is unavailable.
Frontline amivantamab plus lazertinib reduced the risk of disease progression or death by 30% versus osimertinib in patients with high-risk EGFR-mutant non–small cell lung cancer.